Clinical Trials
3 trialsNCT04784715 2026-05-22
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT06174987 2025-10-15
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Daiichi Sankyo
Phase 3 Recruiting
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting